Families affected by catastrophic costs due to tuberculosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Global, regional, and national economic value of reducing amenable tuberculosis mortality.Infectious Disease Modelling · 2026
   Article
2. Inequalities in financial burden of tuberculosis among affected families across 19 low- and middle-income countries.PLOS global public health · 2026
   Article
3. Impact of drug-resistant tuberculosis on socio-economic status, quality of life and psychological well-being of patients in Bucharest, Romania: a prospective cohort study.Journal of health, population, and nutrition · 2024
   Article
4. Cost of TB care and equity in distribution of catastrophic TB care costs across income quintiles in India.Global health research and policy · 2024
   Article

Corrections and comments

• Comment on
  Costs incurred by people receiving tuberculosis treatment in low-income and middle-income countries: a meta-regression analysis.2023

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as